{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:50:52Z","timestamp":1788054652911,"version":"build-2784847793"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Dissecting cellulitis of the scalp (DCS) is a cicatricial alopecia characterized by follicular occlusion that progresses to abscess formation and rupture, driven by an intense inflammatory cascade. Part of the follicular occlusion tetrad, DCS typically presents with painful nodules and interconnecting sinus tracts localized to the scalp. Treatment of this recalcitrant disease is difficult, and there is a need for efficacious and durable therapies that control inflammation and address the underlying pathophysiology of disease. Here is the first reported use of bimekizumab, a dual inhibitor of interleukin (IL)-17A and IL-17F, as monotherapy for the management of DCS. The patient was a male aged 27 years who presented with difficult-to-treat DCS and hair loss. After failing to achieve symptomatic control with standard treatments such as oral antibiotics, aggressive topical therapy, and intralesional steroids, the patient received bimekizumab (320 mg subcutaneously every 2 weeks through week 16, and 320 mg every 4 weeks thereafter). At the 16-week follow-up, the patient reported no symptoms of DCS or adverse events from treatment. The outcomes from our case report provide evidence supporting the inhibition of IL-17A and IL-17F for the treatment of DCS to address the underlying inflammatory mechanism, reduce symptoms, and help patients achieve control over their disease and improve their overall quality of life.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1830178","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:39:41Z","timestamp":1779169181000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Bimekizumab for dissecting cellulitis of the scalp"],"prefix":"10.3389","volume":"17","author":[{"given":"David","family":"Seiter","sequence":"first","affiliation":[{"name":"Epiphany Dermatology","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.101164","article-title":"Dissecting cellulitis of the scalp: A case report","volume":"18","author":"Delgado","year":"2026","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.17161\/kjm.vol17.22560","article-title":"Dissecting cellulitis of the scalp","volume":"17","author":"Jaroonwanichkul","year":"2024","journal-title":"Kansas J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2024.06.003","article-title":"Dissecting cellulitis of the scalp: Clinical characteristics and impact on quality of life of 66 Brazilian patients","volume":"100","author":"Gerlero","year":"2025","journal-title":"Bras Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2021.01.002","article-title":"Are dissecting cellulitis and hidradenitis suppurative different diseases","volume":"39","author":"Federico","year":"2021","journal-title":"Clinics Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13023-025-03720-5","article-title":"A systematic review of tumor necrosis factor-alpha blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment","volume":"20","author":"Heidari","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00403-025-04301-z","article-title":"Off-label use of biologics and Janus kinase (JAK) inhibitors for scarring alopecias: A narrative review","volume":"317","author":"Agarwal","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01018-7","article-title":"Treatments for dissecting cellulitis of the scalp: A systematic review and treatment algorithm","volume":"13","author":"Masson","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.16","article-title":"3 cases of dissecting cellulitis of the scalp treated with adalimumab","volume":"146","author":"Navarini","year":"2010","journal-title":"Arch Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.11.031","article-title":"Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension","volume":"94","author":"Sayed","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2021.NVRN0421","article-title":"An up-to-date approach to the management of dissecting cellulitis","volume":"21","author":"Nussbaum","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S504393","article-title":"Dissecting cellulitis of the scalp successfully treated with a combination of ixekizumab and tofacitinib","volume":"18","author":"Qiu","year":"2025","journal-title":"J Inflammation Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2025.01.002","article-title":"Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders","volume":"83","author":"Saran","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 pathway in inflammatory skin diseases: From bench to bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.585134","article-title":"Interleukin (IL)-12 and IL-18 synergize to promote MAIT cell IL-17A and IL-17F production independently of IL-23 signaling","volume":"11","author":"Cole","year":"2020","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2025.100425","article-title":"Mucosal-associated invariant T (MAIT) cells in skin immunity: Metabolic regulation, tissue adaptation, and roles in skin inflammation and disease","volume":"6","author":"Nanda","year":"2026","journal-title":"JID Innov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae442","article-title":"The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: Evidence from human in vitro preclinical experiments and clinical samples","volume":"192","author":"Rastrick","year":"2025","journal-title":"Br J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad010","article-title":"Guselkumab for hidradenitis suppurativa: A phase ii, open-label, mode-of-action study","volume":"188","author":"Dudink","year":"2023","journal-title":"Br J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.06.014","article-title":"Acne keloidalis nuchae in a patient with atopic dermatitis treated with Janus kinase inhibitor upadacitinib","volume":"38","author":"Caudrelier","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S99225","article-title":"Acne keloidalis nuchae: Prevalence, impact, and management challenges","volume":"9","author":"Ogunbiyi","year":"2016","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1830178\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:39:41Z","timestamp":1779169181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1830178\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2026.1830178"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1830178","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"article-number":"1830178"}}